



Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

ISSN: (Print) (Online) Journal homepage: <https://www.tandfonline.com/loi/iafd20>


ALSUntangled #66: antimycobacterial antibiotics.

Ellen S. Pierce, Paul Barkhaus, Morgan Beauchamp, Mark Bromberg, Gregory T. Carter, Jill Goslinga, David Greeley, Sky Kihuwa-Mani, Gleb Levitsky, Isaac Lund, Christopher McDermott, Gary Pattee, Kaitlyn Pierce, Meraida Polak, Dylan Ratner, Paul Wicks & Richard Bedlack

To cite this article: Ellen S. Pierce, Paul Barkhaus, Morgan Beauchamp, Mark Bromberg, Gregory T. Carter, Jill Goslinga, David Greeley, Sky Kihuwa-Mani, Gleb Levitsky, Isaac Lund, Christopher McDermott, Gary Pattee, Kaitlyn Pierce, Meraida Polak, Dylan Ratner, Paul Wicks & Richard Bedlack (2022): ALSUntangled #66: antimycobacterial antibiotics., Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, DOI: [10.1080/21678421.2022.2104650](https://doi.org/10.1080/21678421.2022.2104650)

To link to this article: <https://doi.org/10.1080/21678421.2022.2104650>

 View supplementary material 

 Published online: 01 Aug 2022.

 Submit your article to this journal 




 View related articles 

 View Crossmark data 



REVIEW ARTICLE

ALSUntangled #66: antimycobacterial antibiotics.

ELLEN S. PIERCE¹ , PAUL BARKHAUS², MORGAN BEAUCHAMP³, MARK BROMBERG⁴, GREGORY T. CARTER⁵, JILL GOSLINGA⁶, DAVID GREELEY⁷, SKY KIHUWA-MANI⁸, GLEB LEVITSKY⁹, ISAAC LUND¹⁰, CHRISTOPHER MCDERMOTT¹¹ , GARY PATTEE¹², KAITLYN PIERCE¹³, MERAIDA POLAK¹⁴, DYLAN RATNER¹⁵, PAUL WICKS¹⁶  & RICHARD BEDLACK¹⁷

¹Spokane Valley, WA, USA, ²Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USA, ³UNC Neurosciences Clinical Trials Unit, University of North Carolina, Chapel Hill, NC, USA, ⁴Department of Neurology, University of Utah, Salt Lake City, UT, USA, ⁵Department of Rehabilitation, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USA, ⁶Department of Neurology, University of California, San Francisco, CA, USA, ⁷Northwest Neurological Associates, PLLC, Spokane, WA, USA, ⁸Undergraduate, UNC-Greensboro, Greensboro, NC, USA, ⁹Real Health Clinic, Moscow, Russia, ¹⁰Undergraduate, Green Hope High School, Cary, NC, USA, ¹¹Department of Neuroscience, University of Sheffield, Sheffield, South Yorkshire, UK, ¹²Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USA, ¹³Department of Neuroscience, University of North Carolina, Chapel Hill, NC, USA, ¹⁴Department of Neurology, Emory University School of Medicine, Emory, GA, USA, ¹⁵Undergraduate, Longmeadow High School, Longmeadow, MA, USA, ¹⁶Independent Consultant, Lichfield, England, UK, and ¹⁷Department of Neurology, Duke University, Durham, NC, USA

Abstract

Several infections have been associated with motor neuron diseases resembling ALS, including species of viruses, bacteria, and parasites. *Mycobacterium avium* subspecies *paratuberculosis* (MAP), most known for its probable etiologic association with Crohn's disease, has been suggested as another possible infectious cause of motor neuron disease. Two published case reports describe the successful treatment of ALS-like symptoms with antimycobacterial antibiotics. Both cases had atypical features. Based on these, we believe it would be reasonable to begin performing chest imaging in PALS who have features of their history or exam that are atypical for ALS such as pain, fevers, or eye movement abnormalities. If the chest imaging is abnormal, more specific testing for mycobacteria may be indicated. Until there is more clear evidence of an association between mycobacteria and ALS, we cannot endorse the widespread use of potentially toxic antimycobacterial antibiotics for PALS.


Keywords: *Amyotrophic lateral sclerosis, antimycobacterial antibiotic therapy, infectious ALS, motor neurone disease, paratuberculosis*

Overview

Species of viruses (1–5), Cyanobacteria (6,7), Mycoplasma (8), Mycobacteria (9,10), Brucella (11), and Schistosoma (12) have all been associated with motor neuron diseases resembling ALS. The theory that *Mycobacterium avium* subspecies *paratuberculosis* (MAP) might cause or trigger ALS was first mentioned in a paper published in 2015

(13) and then described in detail in a paper published in 2018 (14,15). This bacterium is most known for its probable disease-causing-association with Crohn's disease (16,17). Here, on behalf of people with ALS (PALS) who asked about this (18), we review the evidence for mycobacteria in causing an ALS-like illness and the potential of antimycobacterial antibiotics as ALS treatments.

Correspondence: Richard Bedlack, Department of Neurology, Duke University, Durham, NC, USA. Email: richard.bedlack@duke.edu

 Supplemental data for this article can be accessed here <https://doi.org/10.1080/21678421.2022.2104650>

ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS (PALS). Here, we review antimycobacterial antibiotics.

(Received 22 June 2022; accepted 18 July 2022)

Mechanistic plausibility

Apoptosis (a specific form of programmed cell death) rather than necrosis is considered to be the type of motor neuron death in ALS (19). Bacteria can cause neuronal apoptosis via caspase activation and reactive oxygen species (20). A study published in 2004 demonstrated that intracellular MAP organisms can secrete a variant zinc/copper superoxide dismutase that contains copper but completely lacks zinc (21). Zinc-deficient copper containing superoxide dismutases are thought to cause neuronal apoptosis by two possible mechanisms: (1) the induction of nitric oxide production (22), which then causes neuronal apoptosis by oxidant activation of either the p53/p38 MAPK pathway or endoplasmic reticulum stress (23), or (2) the enhanced catalysis of tyrosine nitration by peroxynitrite (24). Given these theoretical mechanisms we assign a Table of Evidence (TOE) grade of D (Table 1). Oddly, some data suggest that MAP has antiapoptotic effects in infected bovine, ovine, and human macrophages (25,26).

Pre-clinical models

There are no studies of antimycobacterial antibiotics in classic pre-clinical animal models of ALS. We therefore assign a “pre-clinical” TOE grade of U (Table 1). Of interest, injection of *Mycobacterium avium* organisms into the foot pads of mice can cause degeneration of their sciatic nerves (27). This somewhat supports the theory that transcutaneous MAP exposure could lead to motor neuron loss in humans (14).

Patient case reports

We found 2 case reports of ALS-like illnesses responding to antimycobacterial antibiotic therapy (9,10). Details of these can be found in the Supplemental Data. Both cases had upper and lower motor neuron signs, but because of atypical features such as eye movement abnormalities, extremity pain, cough, and low grade fevers, chest imaging was performed which eventually led to the

diagnosis of and treatment for *Mycobacterium tuberculosis* (MTB). Based on these published case reports, both of whom had some atypical features for an ALS diagnosis, we assign a TOE “cases” grade of A (Table 1).

Dosing, risks, and costs

Optimal antibiotic dosing for mycobacterial infection in association with motor neuron disease has not been established. The first case report (9) did not describe the particular antibiotics used in the patient’s “anti-tuberculous treatment.” The second case report (10) used two months of isoniazid (225 mg/day total), rifampicin (450mg/day total), ethambutol (825 mg/day total), and pyrazinamide (1200 mg/day total), followed by four additional months of the above regimen minus the pyrazinamide. Details on mycobacterial treatments in other conditions (28–56) can be found in the Supplemental Data.

Rifabutin can cause leukopenia, neutropenia, thrombocytopenia, and hepatitis requiring laboratory monitoring (57). Rifabutin at the high dose of 600 mg/day, especially in combination with a macrolide antibiotic such as clarithromycin, can result in reversible anterior uveitis in a significant proportion of patients depending on their immune status (58,59). The treatment of drug-induced uveitis “occasionally” involves hospitalization (60). Clarithromycin can cause a metallic taste, 10% of patients may have nausea, diarrhea, abdominal pain, and/or headache (61), and there is an increased rate of sudden cardiac death compared to other antibiotics of 37/million clarithromycin doses (62). Clofazimine almost always causes brownish skin discoloration, and sometimes abdominal pain, but these side effects led to discontinuation of treatment in only 0.1% of patients (63). Nausea, vomiting, diarrhea, and abdominal pain are common side effects of metronidazole (64). Encephalopathy (65) and optic neuropathy (66) are rare side effects of metronidazole and are usually reversible with discontinuation of the drug. Based on these rare but potentially serious side effects, we assign a TOE “risks” grade of D

Table 1. Table of evidence for antimycobacterial antibiotics.

	Grade	Explanation
Mechanism	D	MAP can theoretically cause motor neuron death via apoptosis by secreting zinc absent copper containing SOD; oddly some data suggest that MAP can also be anti-apoptotic.
Pre-Clinical Cases	U	We found no studies of anti-MAP therapy in ALS models.
	A	Two case studies of patients with MTB and atypical ALS symptoms had the latter improve with antimycobacterial antibiotics.
Trials	U	We found no clinical trials of antimycobacterial antibiotics in PALS.
Risks	D	Rare antibiotic-associated encephalopathy (metronidazole). Rare sudden cardiac death (clarithromycin). Rare optic neuropathy (metronidazole). Frequent uveitis (rifabutin) in immunocompromised patients occasionally requiring hospitalization.

(Table 1). Of additional interest, one case-control study suggests that any antibiotic use might increase the risk of developing ALS as well (67).

The cash price of rifabutin (68) in the U.S. is approximately 1200 US dollars for 100 150 mg capsules or 1440 dollars per month for four capsules (600 mg) per day. The cash price of clarithromycin (69) is approximately 30 US dollars for twenty 500 mg tablets or 90 dollars per month for two tablets (1000 mg) per day. Although the World Health Organization classifies clofazimine as an essential medicine (70), it is only available in the United States as an investigational new drug via Novartis' Managed Access Program (71). It is provided to patients under this program at no cost. The cash price for metronidazole (72) is approximately ten dollars per 500 mg tablet, or 600 US dollars per month for two tablets (1000 mg) per day.

Conclusion

There is a theorized association between MAP and ALS, and two published case reports described improvements in ALS-like conditions (both with atypical features) after treatment with antimycobacterial antibiotics. Based on these, we believe it would be reasonable to perform chest imaging in PALS who have features of their history or exam that are atypical for ALS such as pain, fevers, or eye movement abnormalities. If the chest imaging is abnormal, more specific testing for mycobacteria may be indicated. Until there is more clear evidence of an association between MAP and ALS, we cannot endorse the widespread use of potentially toxic antimycobacterial antibiotics for PALS.

Declaration of interest

Richard Bedlack has research support from ALSA, Orion, MediciNova, and the Healey Center, and consulting support from AB Science, Alexion, ALSA, Amylyx, Biogen, Brainstorm Cell, Corcept, GenieUS, Guidepoint, ITF Pharma, Mallinkrodt, New Biotic, Orphazyme, and Woolsey Pharma. Other authors report no disclosures or conflicts of interest.

The authors alone are responsible for the content and writing of this article.

Funding

ALSUntangled is sponsored by the Amyotrophic Lateral Sclerosis Association.

ORCID

Ellen S. Pierce  <http://orcid.org/0000-0003-2045-191X>

Christopher McDermott  <http://orcid.org/0000-0002-1269-9053>

Paul Wicks  <http://orcid.org/0000-0002-2293-9284>

References

1. Castanedo-Vazquez D, Bosque-Varela P, Sainz-Pelayo A, Riancho J. Infectious agents and amyotrophic lateral sclerosis: another piece of the puzzle of motor neuron degeneration. *J Neurol*. 2019;266:27–36.
2. Jubelt B, Berger JR. Does viral disease underlie ALS? Lessons from the AIDS pandemic. *Neurology* 2001;57: 945–6.
3. Xue YC, Feuer R, Cashman N, Luo H. Enteroviral infection: the forgotten link to amyotrophic lateral sclerosis? *Front Mol Neurosci*. 2018; 11:63.
4. Matyja E, Laure-Kamionowska M. Post-polio syndrome and amyotrophic lateral sclerosis – similarities, differences and diagnostic dilemmas. http://postpolio.lublin.pl/PPS-conf/Abstract_PPS.ALS_en.pdf. Accessed June 25, 2018.
5. Moulignier A, Moulouguet A, Pialoux G, Rozenbaum W. Reversible ALS-like disorder in HIV infection. *Neurology* 2001;57:995–1001.
6. Sini P, Dang TBC, Fais M, Galioto M, Padedda BM, Lugliè A, et al. Cyanobacteria, cyanotoxins, and neurodegenerative diseases: dangerous liaisons. *Int J Mol Sci*. 2021;22:8726.
7. Bradley WG, Mash DC. Beyond Guam: the cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases. *Amyotroph. Lateral Scler*. 2009;10:7–20.
8. Nicolson GL, Nasralla MY, Haier J, Pomfret J. High frequency of systemic mycoplasmal infections in Gulf War veterans and civilians with Amyotrophic Lateral Sclerosis (ALS). *J Clin Neurosci*. 2002;9:525–9.
9. Ren J, Shen C, Che G. A rare case of tuberculosis with motor neuron disease. *World J Surg Oncol*. 2014;12: 381–3.
10. Peer S, Nagaraj C, Mangalore S. Hybrid PET/MRI findings in a case of pulmonary and extra-pulmonary tuberculosis associated with motor-neuron disease-like illness – a coincidence or a causation?: A case report. *Egypt J Radiol Nucl Med*. 2021;52:1–6.
11. Argyriou AA, Karanasios P, Papapostolou A, Loukopoulou P, Makridou A, Marangos M, et al. Neurobrucellosis presenting as clinically definite amyotrophic lateral sclerosis. *Int J Neurosci*. 2018; 128: 686–3.
12. Moling O, Di Summa A, Capone L, Stuefer J, Piccin A, Porzia A, et al. Increased IL-17, a pathogenic link between hepatosplenic schistosomiasis and amyotrophic lateral sclerosis: a hypothesis. *Case Reports Immunol*. 2014; 2014:804761.
13. Kuenstner JT, Chamberlin W, Naser SA, Collins MT, Dow CT, Aitken JM, et al. Resolution of Crohn's disease and complex regional pain syndrome following treatment of paratuberculosis. *World J Gastroenterol*. 2015;21: 4048–62.
14. Pierce ES. How did Lou Gehrig get Lou Gehrig's disease? *Mycobacterium avium* subspecies paratuberculosis in manure, soil, dirt, dust and grass and amyotrophic lateral sclerosis (motor neurone disease) clusters in football, rugby and soccer players. *Med Hypotheses*. 2018;119:1–5.
15. Pierce ES. *Mycobacterium avium* subspecies paratuberculosis as a soil bacteria and ALS clusters in outdoor sports players. <http://sciencetrends.com/mycobacterium-avium-subspecies-paratuberculosis-as-a-soil-bacteria-and-als-clusters-in-outdoor-sports-players/>. Accessed January 3, 2022.

16. Kuenstner JT, Naser S, Chamberlin W, Borody T, Graham DY, McNees A, et al. The Consensus from the *Mycobacterium avium* ssp. *paratuberculosis* (MAP) Conference 2017. *Front Public Health*. 2017; 5:208.
17. Agrawal G, Aitken J, Hamblin H, Collins M, Borody TJ. Putting Crohn's on the MAP: five common questions on the contribution of *mycobacterium avium* subspecies *paratuberculosis* to the Pathophysiology of Crohn's Disease. *Dig Dis Sci*. 2021;66:348–58.
18. ALSUntangled Online. Future Reviews. <http://www.alsuntangled.com/future-reviews/>. Accessed June 15, 2022.
19. Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. *J Neuropathol Exp Neurol*. 1999;58:459–71.
20. Parthasarathy G, Philipp MT. Review: apoptotic mechanisms in bacterial infections of the central nervous system. *Front Immunol*. 2012;3:306.
21. Spagnolo L, Törö I, D'Orazio M, O'Neill P, Pedersen JZ, Carugo O, et al. Unique features of the *sodC*-encoded superoxide dismutase from *Mycobacterium tuberculosis*, a fully functional copper-containing enzyme lacking zinc in the active site. *J Biol Chem*. 2004;279:33447–55.
22. Estévez AG, Crow JP, Sampson JB, Reiter C, Zhuang Y, Richardson GJ, et al. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. *Science*. 1999;286:2498–500.
23. Brown GC. Nitric oxide and neuronal death. *Nitric Oxide*. 2010;23:153–65.
24. Crow JP, Sampson JB, Zhuang Y, Thompson JA, Beckman JS. Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. *J Neurochem*. 1997;69:1936–44.
25. Abendaño N, Juste RA, Alonso-Hearn M. Anti-inflammatory and antiapoptotic responses to infection: a common denominator of human and bovine macrophages infected with *Mycobacterium avium* subsp. *Biomed Res Int*. 2013;2013:908348.
26. Abendaño N, Tyukalova L, Barandika JF, Balseiro A, Sevilla IA, Garrido JM, et al. *Mycobacterium avium* subsp. *paratuberculosis* isolates induce in vitro granuloma formation and show successful survival phenotype, common anti-inflammatory and antiapoptotic responses within ovine macrophages regardless of genotype or host of origin. *PLoS One*. 2014;9:e104238.
27. Kamala AN, Antia NH, Shetty VP. Study of the involvement of the sciatic nerve following inoculation with *M. leprae* and other mycobacteria in the mouse foot pad. *Int J Leprosy Other Mycobacter Diseases* 1984;52:506–14.
28. Rastogi N, Goh KS, Labrousse V. Activity of clarithromycin compared with those of other drugs against *Mycobacterium paratuberculosis* and further enhancement of its extracellular and intracellular activities by ethambutol. *Antimicrob Agents Chemother*. 1992;36:2843–6.
29. Zanetti S, Molicotti P, Cannas S, Ortu S, Ahmed N, Sechi LA. "In vitro" activities of antimycobacterial agents against *Mycobacterium avium* subsp. *paratuberculosis* linked to Crohn's disease and *paratuberculosis*. *Ann Clin Microbiol Antimicrob*. 2006;5:27.
30. Beckler DR, Elwasila S, Ghobrial G, Valentine JF, Naser SA. Correlation between *rpoB* gene mutation in *Mycobacterium avium* subspecies *paratuberculosis* and clinical rifabutin and rifampicin resistance for treatment of Crohn's disease. *World J Gastroenterol*. 2008;14:2723–30.
31. Chiodini RJ. Bactericidal activities of various antimicrobial agents against human and animal isolates of *Mycobacterium paratuberculosis*. *Antimicrob Agents Chemother*. 1990;34:366–7.
32. Warren JB, Rees HC, Cox TM. Remission of Crohn's disease with tuberculosis chemotherapy. *N Engl J Med*. 1986;314:182.
33. Hampson SJ, Parker MC, Saverymuttu SH, Joseph AE, McFadden JJ, Hermon-Taylor J. Quadruple antimycobacterial chemotherapy in Crohn's disease: results at 9 months of a pilot study in 20 patients. *Aliment Pharmacol Ther*. 1989;3:343–52.
34. Schultz MG, Rieder HL, Hersh T, Riepe S. Remission of Crohn's disease with antimycobacterial chemotherapy. *Lancet*. 1987;2:1391–2.
35. Picciotto A, Gesu GP, Schito GC, Testa R, Varagona G, Celle G. Antimycobacterial chemotherapy in inflammatory bowel disease. *Biomed Pharmacother*. 1989;43:141–3.
36. Wirostko E, Johnson L, Wirostko B. Crohn's disease. Rifampin treatment of the ocular and gut disease. *Hepatology*. 1987;34:90–3.
37. Gupta S, Chaubey KK, Agarwal P, Kuenstner JT, Parashar D, Singh SV. Therapeutic management of *Mycobacterium avium* subspecies *paratuberculosis* infection with complete resolution of symptoms and disease in a patient with advanced inflammatory bowel syndrome. *Mol Biol Rep*. 2021;48:7013–20.
38. Williams SL, Harris NB, Barletta RG. Development of a firefly luciferase-based assay for determining antimicrobial susceptibility of *Mycobacterium avium* subsp. *J Clin Microbiol*. 1999;37:304–9.
39. Sadun AA, Wang MY. Ethambutol optic neuropathy: how we can prevent 100,000 new cases of blindness each year. *J Neuroophthalmol*. 2008;28:265–8.
40. Krishnan MY, Manning EJ, Collins MT. Comparison of three methods for susceptibility testing of *Mycobacterium avium* subsp. *paratuberculosis* to 11 antimicrobial drugs. *J Antimicrob Chemother*. 2009;64:310–6.
41. Zhang Y, Scorpio A, Nikaido H, Sun Z. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of *Mycobacterium tuberculosis* to pyrazinamide. *J Bacteriol*. 1999;181:2044–9.
42. Lamont EA, Dillon NA, Baughn AD. The bewildering antitubercular action of pyrazinamide. *Microbiol Mol Biol Rev*. 2020;84:e00070-19.
43. Honap S, Johnston E, Agrawal G, Al-Hakim B, Hermon-Taylor J, Sanderson J. Anti-*Mycobacterium paratuberculosis* (MAP) therapy for Crohn's disease: an overview and update. *Frontline Gastroenterol*. 2021;12:397–403.
44. Alcedo KP, Thanigachalam S, Naser SA. RHB-104 triple antibiotics combination in culture is bactericidal and should be effective for treatment of Crohn's disease associated with *Mycobacterium paratuberculosis*. *Gut Pathog*. 2016; 8:32.
45. Qasem A, Safavikhasraghi M, Naser SA. A single capsule formulation of RHB-104 demonstrates higher antimicrobial growth potency for effective treatment of Crohn's disease associated with *Mycobacterium avium* subspecies *paratuberculosis*. *Gut Pathog*. 2016; 8:45.
46. Savarino E, Bertani L, Ceccarelli L, Bodini G, Zingone F, Buda A, et al. Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for *Mycobacterium avium* subspecies *paratuberculosis* in Crohn's disease: pharmacological and clinical implications. *Expert Opin Biol Ther*. 2019;19:79–88.
47. Agrawal G, Clancy A, Sharma R, Huynh R, Ramrakha S, Borody T. Targeted combination antibiotic therapy induces remission in treatment-naïve Crohn's disease: a case series. *Microorganisms* 2020;8:371.
48. Borody TJ, Bilkey S, Wettstein AR, Leis S, Pang G, Tye S. Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars. *Dig Liver Dis*. 2007;39:438–44.

49. Agrawal G, Hamblin H, Clancy A, Borody T. Antimycobacterial antibiotic therapy induces remission in active Paediatric Crohn's Disease. *Microorganisms* 2020;8:1112.
50. Collyer R, Clancy A, Agrawal G, Borody TJ. Crohn's strictures open with anti-mycobacterial antibiotic therapy: a retrospective review. *World J Gastrointest Endosc.* 2020;12:542–54.
51. Thia KT, Mahadevan U, Feagan BG, et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. *Inflamm. Bowel Dis* 2009;15:17–24.
52. Prantero C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. *Am J Gastroenterol* 1996;91:328–32.
53. Chopra S, Matsuyama K, Hutson C, Madrid P. Identification of antimicrobial activity among FDA-approved drugs for combating *Mycobacterium abscessus* and *Mycobacterium chelonae*. *J Antimicrob Chemother.* 2011;66:1533–6.
54. Parrish N, Vadlamudi A, Goldberg N. Anaerobic adaptation of *Mycobacterium avium* subspecies paratuberculosis in vitro: similarities to *M. tuberculosis* and differential susceptibility to antibiotics. *Gut Pathog.* 2017; 9:34.
55. World Health Organization – Regional Office for South-East Asia. Guidelines for the diagnosis, treatment and prevention of leprosy (2017).
56. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med.* 2007;175:367–416.
57. Toronto General Hospital Immunodeficiency Clinic. Rifabutin. http://hivclinic.ca/main/drugs_fact_files/rifabutin.pdf. Accessed May 6, 2022.
58. Griffith DE, Brown BA, Girard WM, Wallace RJ. Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of *Mycobacterium avium* complex lung disease. *Clin Infect Dis.* 1995;21:594–8.
59. Rihani HT, Smith WM. Drug-induced uveitis: part 2: Cidofovir, rifabutin, sulfonamides, bisphosphonates, fluoroquinolones, intravitreal anti-vascular endothelial growth factor, and topical antiglaucoma medications. *Adv Ophthalmol Optometry* 2020;2020:5307–30.
60. London NJ, Garg SJ, Moorthy RS, Cunningham ET. Drug-induced uveitis. *J Ophthalmic Inflamm Infect.* 2013; 3:18–43.
61. Guay DR, Patterson DR, Seipman N, Craft JC. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. *Drug Saf.* 1993;8:350–64.
62. Svanstrom H, Pasternak B, Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. *BMJ.* 2014;349:g4930. 349g4930.
63. Hwang TJ, Dotsenko S, Jafarov A, Weyer K, Falzon D, Lunte K, et al. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies. *BMJ Open.* 2014;4:e004143.
64. MedLine Plus – National Library of Medicine (US). Metronidazole. <http://medlineplus.gov/druginfo/meds/a689011.html>. Accessed April 18, 2022.
65. Sorensen CG, Karlsson WK, Amin FM, Lindelof M. Metronidazole-induced encephalopathy: a systematic review. *J Neurol.* 2020;267:1–13.
66. McGrath NM, Kent-Smith B, Sharp DM. Reversible optic neuropathy due to metronidazole. *Clin Exp Ophthalmol.* 2007;35:585–6.
67. Sun J, Zhan Y, Mariosa D, Larsson H, Almqvist C, Ingre C, et al. Antibiotics use and risk of amyotrophic lateral sclerosis in Sweden. *Eur J Neurol.* 2019;26:1355–61.
68. Drugs.com. Rifabutin prices, coupons, and patient assistance programs. <http://www.drugs.com/price-guide/rifabutin#:~:text=The%20cost%20for%20rifabutin%20oral,not%20valid%20with%20insurance%20plans>. Accessed April 18, 2022.
69. Drugs.com. Clarithromycin prices, coupons, and patient assistance programs. <https://www.drugs.com/price-guide/clarithromycin>. Accessed April 19, 2022.
70. World Health Organization. World Health Organization Model List of Essential Medicines. <http://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf>.
71. Nontuberculous Mycobacteria Info & Research Inc. Access to clofazimine. <http://ntminfo.org/your-treatment-the-emphasis-on-you-2/>. Accessed April 17, 2022.
72. Drugs.com. Metronidazole prices, coupons, and patient assistance programs. <http://www.drugs.com/price-guide/metronidazole>. Accessed April 19, 2022.